From Science Daily:
Renal cell carcinomas positive for the protein PD-L1 from patients who did not respond to treatment with the anti-PD-1 therapeutic nivolumab (Opdivo) had significantly higher expression of genes associated with metabolism, compared with PD-L1-positive tumors from patients who did respond to nivolumab, according to a clinical study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.
Read the full article.
